BCI
Based on 17 publication(s) in Google Scholar
BCI ((E)-BCI) is a DUSP6 (dual specificity phosphatase 6) inhibitor. BCI shows anti-inflammatory activity and decreases reactive oxygen species (ROS) production. BCI can be used in inflammatory disease research.
For research use only. We do not sell to patients.
- Purity: 99.73%
- CAS No.: 1245792-51-1
- Formula: C22H23NO
- Molecular Weight:317.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Pyroptosis Compound Library
HY-L059
-
Phosphatase Inhibitor Library
HY-L081
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) BCI
More- Signal Transduct Target Ther. 2026 Mar 17;11(1):100. [Abstract]
- J Nanobiotechnology. 2025 Jun 6;23(1):422. [Abstract]
- Cell Rep. 2025 Feb 20;44(3):115340. [Abstract]
- Neural Regen Res. 2023 Aug;18(8):1743-1749. [Abstract]
- Phytother Res. 2023 Jul;37(7):2979-2994. [Abstract]
- Cells. 2022 Feb 19;11(4):732. [Abstract]
- Int Immunopharmacol. 2024 Sep 30;143(Pt 1):113280. [Abstract]
- Cancers (Basel). 2023 Sep 6;15(18):4442. [Abstract]
- FASEB J. 2025 Jul 15;39(13):e70780. [Abstract]
- Sci Rep. 2025 May 24;15(1):18115. [Abstract]
- Development. 2023 Mar 1;150(5):dev201090. [Abstract]
- Dis Model Mech. 2023 May 1;16(5):dmm049662. [Abstract]
- Cancer Med. 2024 Oct;13(19):e70276. [Abstract]
- Kaohsiung J Med Sci. 2023 Mar;39(3):254-265. [Abstract]
- Transplant Proc. 2025 Aug 11:S0041-1345(25)00350-1. [Abstract]
- University of Washington. 2025.
- bioRxiv. 2024 Feb 5.
Customer Validation & Images
-
WB
-
WB
-
IF
-
Cell Proliferation/Viability Assay
-
IF
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
11.5 μM
Compound: 1, BCI
|
Inhibition of Myc-tagged human Dusp1 expressed in TPA-induced human HeLa cells assessed as decrease in dephosphorylation of pERK measured by immunostaining
Inhibition of Myc-tagged human Dusp1 expressed in TPA-induced human HeLa cells assessed as decrease in dephosphorylation of pERK measured by immunostaining
|
[PMID: 19578332] |
| HeLa | IC50 |
12.3 μM
Compound: 1, BCI
|
Inhibition of Myc-tagged human Dusp6 expressed in TPA-induced human HeLa cells assessed as decrease in dephosphorylation of pERK measured by immunostaining
Inhibition of Myc-tagged human Dusp6 expressed in TPA-induced human HeLa cells assessed as decrease in dephosphorylation of pERK measured by immunostaining
|
[PMID: 19578332] |
BCI (100 ng/mL; 24 h) downregulats the expression of DUSP6 in RAW264.7 macrophage cells[2].
?
BCI (0-1 nM; 24 h) inhibits the expression of IL-1β and IL-6 in lipopolysaccharide- (LPS-) activated macrophages[2].
?
BCI (0-4 nM; 24 h) decreases ROS production and activates the Nrf2 Pathway in LPS-activated macrophages[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 macrophage cells
-
Concentration:100 ng/mL
-
Incubation Time:24 hours
-
Result:Showed DUSP6 protein downregulation.
-
Cell Line:RAW264.7 macrophage cells
-
Concentration:0-1 nM
-
Incubation Time:24 hours
-
Result:Inhibited the expression of IL-1β and IL-6 mRNA in LPS-activated macrophages.
Chemical Information
-
CAS No. 1245792-51-1
-
Appearance Solid
-
Molecular Weight 317.43
-
Formula C22H23NO
-
Color Off-white to yellow
-
SMILES
O=C1/C(C(NC2CCCCC2)C3=C1C=CC=C3)=C/C4=CC=CC=C4
-
Synonyms
(E)-BCI
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling. [Abstract]2026 Mar 17;11(1):100. PMID: 41844571 -
J Nanobiotechnology
Remote ischemia precondition protects against renal IRI through apoptosis associated vesicles carrying MIF protein via modulating DUSP6/JNK signaling axis. [Abstract]2025 Jun 6;23(1):422. PMID: 40481499
BCI purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jun 6;23(1):422. [Abstract]
Western blots and densitometry analysis of JNK and p-JNK in HK-2 cells, co-cultured with MIF-WT or MIF-KO ACPSVs, treated with or without BCI, subjected to H/R.
BCI purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Jun 6;23(1):422. [Abstract]
Western blots and densitometry analysis of Bcl-2, Bax and C-Cas 3 in HK-2 cells, co-cultured with MIF-WT or MIF-KO ACPSVs, treated with or without BCI, subjected to H/R.
-
Cell Rep
Restraint of inflammasome-driven cytokine responses through the mRNA stability protein TTP. [Abstract]2025 Feb 20;44(3):115340. PMID: 39982821 -
Neural Regen Res
Overexpression of mitogen-activated protein kinase phosphatase-1 in endothelial cells reduces blood-brain barrier injury in a mouse model of ischemic stroke. [Abstract]2023 Aug;18(8):1743-1749. PMID: 36751800
BCI purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2023 Aug;18(8):1743-1749. [Abstract]
Occludin expression was measured 12 hours after OGD by immunofluorescence assay. The OGD-induced reduction in occludin expression was worsened by BCI (1 μM).
BCI purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2023 Aug;18(8):1743-1749. [Abstract]
HBMECs were subjected to 60 minutes of OGD followed by reperfusion. The cells were treated with 1 μM of the MKP-1 inhibitor BCI and 10 nM of the ERK1/2 inhibitor Ravoxertinib during and after OGD; 0.1% DMSO was used as the drug vehicle. Cells were maintained in glucose+/FBS+ medium with 95% air as the normoxic control. Assessment of endothelial cell viability by CCK-8 (n = 6/group).
BCI purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2023 Aug;18(8):1743-1749. [Abstract]
BMECs were subjected to 60 minutes of OGD followed by reperfusion. The cells were treated with 1 μM of the MKP-1 inhibitor BCI and 10 nM of the ERK1/2 inhibitor ravoxertinib during and after OGD; 0.1% DMSO was used as the drug vehicle. Cells were maintained in glucose+/FBS+ medium with 95% air as the normoxic control. Cleaved caspase-3 (Asp175) expression (red, Alexa Fluor 594) was assessed by immunofluorescence. DAPI (blue) was used as a nuclear marker (n = 5/group).
-
Phytother Res
Aloe-emodin targets multiple signaling pathways by blocking ubiquitin-mediated degradation of DUSP1 in nasopharyngeal carcinoma cells. [Abstract]2023 Jul;37(7):2979-2994. PMID: 36866539 -
Cells
Repeated Social Defeat Enhances CaCl2-Induced Abdominal Aortic Aneurysm Expansion by Inhibiting the Early Fibrotic Response via the MAPK-MKP-1 Pathway. [Abstract]2022 Feb 19;11(4):732. PMID: 35203381 -
Int Immunopharmacol
GSDMB interacts with IGF2BP1 to suppress colorectal cancer progression by modulating DUSP6-ERK pathway. [Abstract]2024 Sep 30;143(Pt 1):113280. PMID: 39353395 -
Cancers (Basel)
In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments. [Abstract]2023 Sep 6;15(18):4442. PMID: 37760412 -
FASEB J
Genome-Wide CRISPR-Cas9 Knockout Screening Identifies Genes Modulating Cisplatin-Induced Cytotoxicity in Renal Proximal Tubule Epithelial Cells. [Abstract]2025 Jul 15;39(13):e70780. PMID: 40632661 -
Sci Rep
Integration of network pharmacology, transcriptomics, and experimental verification to investigate the mechanism of action of cepharanthine hydrochloride against prostate cancer. [Abstract]2025 May 24;15(1):18115. PMID: 40413339 -
Development
A distinct transcriptome characterizes neural crest-derived cells at the migratory wavefront during enteric nervous system development. [Abstract]2023 Mar 1;150(5):dev201090. PMID: 36779913 -
Dis Model Mech
A DUSP6 inhibitor suppresses inflammatory cardiac remodeling and improves heart function after myocardial infarction. [Abstract]2023 May 1;16(5):dmm049662. PMID: 36478044 -
Cancer Med
2024 Oct;13(19):e70276. PMID: 39377541 -
Kaohsiung J Med Sci
2023 Mar;39(3):254-265. PMID: 36524461
BCI purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Mar;39(3):254-265. [Abstract]
BCI (8 μM) reverses FAM3D-induced inhibition of gluconeogenesis and expression of DUSP1 in HepG2 cells.
-
Transplant Proc
2025 Aug 11:S0041-1345(25)00350-1. PMID: 40796392 -
-
Solvent & Solubility
DMSO : 125 mg/mL (393.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (6.55 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45. [Content Brief]
[2]. Zhang F, et al. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42(2):672-681. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1503 mL | 15.7515 mL | 31.5030 mL | 78.7575 mL |
| 5 mM | 0.6301 mL | 3.1503 mL | 6.3006 mL | 15.7515 mL | |
| 10 mM | 0.3150 mL | 1.5752 mL | 3.1503 mL | 7.8758 mL | |
| 15 mM | 0.2100 mL | 1.0501 mL | 2.1002 mL | 5.2505 mL | |
| 20 mM | 0.1575 mL | 0.7876 mL | 1.5752 mL | 3.9379 mL | |
| 25 mM | 0.1260 mL | 0.6301 mL | 1.2601 mL | 3.1503 mL | |
| 30 mM | 0.1050 mL | 0.5251 mL | 1.0501 mL | 2.6253 mL | |
| 40 mM | 0.0788 mL | 0.3938 mL | 0.7876 mL | 1.9689 mL | |
| 50 mM | 0.0630 mL | 0.3150 mL | 0.6301 mL | 1.5752 mL | |
| 60 mM | 0.0525 mL | 0.2625 mL | 0.5251 mL | 1.3126 mL | |
| 80 mM | 0.0394 mL | 0.1969 mL | 0.3938 mL | 0.9845 mL | |
| 100 mM | 0.0315 mL | 0.1575 mL | 0.3150 mL | 0.7876 mL |
Powered by Bioz